Other COVID-19 Related Guidelines, Protocols, and Best Practices
LAC DPH Resources for SNFs
4/27/23
These guidelines outline actions that Skilled Nursing Facilities (SNFs) should take to help prevent and manage COVID-19, based on the current status of and trends in community transmission in LA County.
The current CDC COVID-19 Community Level for Los Angeles County can be found here: http://publichealth.lacounty.gov/media/Coronavirus/data/response-plan.htm
A case is defined as an individual with a positive viral test (e.g., PCR/NAAT or antigen test) regardless of symptoms unless a confirmatory PCR/NAAT test is negative for an asymptomatic individual with a positive antigen test.
The separation of persons with COVID-19 from persons without COVID-19. Isolation measures in SNFs include restricting the resident to their room, infected residents wearing well-fitting masks indoors when not in their rooms, and staff donning full PPE prior to providing care or entering rooms where there are infected persons (i.e., placing on transmission-based precautions). Please see “Isolation and Quarantine” section below for more details.
Quarantine keeps asymptomatic persons who might have been exposed to SARS-CoV-2 away from others to see if they become infected. Quarantine in SNFs, when required, involves restricting the resident to their room as much as possible, wearing well-fitting masks indoors when not in their rooms, and staff donning full PPE prior to providing care or entering rooms where there are exposed persons (i.e., placing on transmission-based precautions). Residents in quarantine should be managed in-place; avoid movement of residents to different rooms that could lead to new exposures. Please see “Isolation and Quarantine” section below for more details.
An individual is considered up to date with COVID-19 vaccines when they have received all recommended doses recommended for them by the CDC.
Staying up to date with COVID-19 vaccine doses is critical to protecting both residents and staff in SNFs. The latest COVID-19 vaccine clinical recommendations are located on CDC’s website: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the US. Below are key COVID-19 vaccine guidance and resources for SNFs in LA County.
Visit CDPH vaccine schedules in English and Spanish. Additional vaccine resources from are located on the DPH vaccine resources page.
Offer, Track, and Report COVID-19 Vaccination Doses
Resources for enrolling and reporting in CAIR2 as a front-end user:
Antiviral Treatment
There are highly effective outpatient COVID-19 antiviral treatments to prevent severe outcomes, including hospitalizations and death among high-risk individuals infected with COVID-19 including nursing home residents. The preferred outpatient treatment is ritonavir-boosted nirmatrelvir (Paxlovid), an oral antiviral, or intravenous remdesivir. Molnupiravir (Lagevrio) is an alternative if these preferred treatments are not appropriate, feasible to use, or clinically appropriate. See NIH COVID-19 Treatment Guidelines Antiviral Agents Summary Recommendations.
Per CDPH AFL 22-20 (COVID-19 Treatment Resources for SNFs), all SNF residents with a diagnosis of mild to-moderate COVID-19 are eligible for outpatient antiviral treatment and should be evaluated by a prescribing clinician to start treatment. Because the oral antiviral therapies need to be started within five (5) days of symptom onset (remdesivir is within 7 days of symptom onset), it is crucial for prescribing clinicians to assess residents for COVID-19 as soon as they become symptomatic. Patients that are unable to receive Paxlovid should be treated with either remdesivir or molnupiravir if eligible. See LAC DPH’s COVID-19 Outpatient Therapeutics page for more detailed information.
Facilities should not transfer residents to hospitals solely for treatment of mild or moderate COVID-19. Residents should be treated at their SNF.
To ensure facilities are compliant with CDPH AFL 22-20 and best practices, facilities should:
Residents with COVID-19 may also be assessed for and offered IV remdesivir. Given the emergence of variants resistant to monoclonal antibodies, providing remdesivir in the outpatient setting may be of particular importance for facilities with severely immunosuppressed patients or high-risk pediatric populations.
For more information please see LAC DPH’s COVID-19 Outpatient Therapeutics page and NIH’s Therapeutic Management of Nonhospitalized Adults with COVID-19 for the most up to date information.
Pre-exposure Prophylaxis
Currently, there are no products authorized or approved for use as pre-exposure prophylaxis for COVID-19.
The following general and COVID-19 specific recommendations based on the following:
For more information on infection prevention and control (IPC) basics and the difference between standard and transmission-based precautions, visit https://www.cdc.gov/infectioncontrol/basics/index.html.
General Requirements
Source Control
Residents
Staff
Visitors
Hand Hygiene (HH)
Transmission Based Precautions and Personal Protective Equipment (PPE)
HCP should follow transmission-based precautions for residents in isolation including standard precautions as summarized in table 1 and detailed below.
Table 1. Transmission Based Precautions, PPE, and Resident Placement for COVID-19
Transmission Based Precautions, PPE, Resident Placement | Recommended Signage | |
---|---|---|
Isolation Separation of people confirmed or suspected to be infected with a contagious disease from people who are not infected. |
*If working in dedicated COVID-19 isolation area (formerly “Red Zones”) where resident doors cannot be safely closed at all times or residents frequently leave their rooms, then it is recommended to treat the entire COVID-19 isolation area as a single resident care area where staff dons a new N95 prior to entry and doffs (discards) upon exit of the area. If followed, this should be explained in a risk assessment as a part of the facility’s written mitigation plan. |
COVID-19 Transmission-Based Precautions![]() |
Quarantine Separation of people who were exposed to a contagious disease to see if they become sick. |
For COVID-19, quarantine is not routinely recommended. Public Health may direct individual facilities on a case-by-case basis to quarantine residents in certain risk groups (see table 4 below) to help control transmission in an outbreak. Regardless of whether quarantine is implemented:
|
Only if a resident is placed in quarantine, then infection control signage (e.g., COVID-19 transmission-based precautions) is indicated. Avoid the use of “Yellow Zone” or “Green Zone” signs that may not accurately communicate COVID-19 risk levels and negatively affect adherence to basic infection prevention and control. |
Ventilation, Filtration, and Air Quality: Effective ventilation is one of the most important ways to control small aerosol transmission. Nonetheless, ventilation and other indoor air quality improvements are additions to and not replacements for infection prevention and control including any applicable state or local directives. Please carefully review in full the following guidance from CDPH, Department of Health Care Access and Information (HCAI) formerly OSHPD, and Cal/OSHA: Interim Guidance for Ventilation, Filtration, and Air Quality in Indoor Environments.
Please note SNFs have a second opportunity to apply for Civil Money Penalty (CMP) Reinvestment funds to purchase portable fans and portable room air cleaners with high-efficiency particulate air (HEPA, H-13 or -14) filters to increase air exchange or improve air quality. Facilities should only use portable air cleaners with the involvement of professionals* and following the above state guidance. While portable air cleaners may help when used correctly, facilities should not rely on any single solution to effectively improve the ventilation and air quality of their buildings. Facilities should consult with professionals* to perform comprehensive evaluations of their HVAC (Heating, Ventilation, and Air Conditioning) systems and indoor air quality and obtain permits or approvals from any applicable regulatory bodies as necessary prior to implementing changes.
*Professionals: facilities engineers, mechanical engineers, indoor air quality or industrial hygiene consultants, etc.
Environmental cleaning:
Please refer to CDC guidelines on environmental infection control: https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html#anchor_1604360721943.
For a list of EPA-registered disinfectants that have qualified for use against SARS-CoV-2 (the COVID-19 pathogen) go to: https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2. Products should always be used according to manufacturer’s instructions; disinfectants may not have proper effectiveness against SARS-CoV-2 if manufacturer’s instructions are not followed.
The following recommendations for communal dining, group activities, and visitation are based upon the following:
Resident Rights
Facilities may not restrict visitation or suspend communal dining and group activities without a reasonable clinical or safety cause, consistent with resident rights in the federal regulation Title 42 CFR section 483.10(f)(4)(v) as referenced in CMS QSO 20-39-NH-Revised. To mitigate risks to other, visitation, communal dining, and group activities should be conducted adhering to the “Core Principles of COVID-19 Infection Prevention” by following the guidance in this section and the rest of this guidance including but not limited to the “Infection Prevention and Control Guidance” section.
Communal Dining and Group Activities
Residents who are in isolation, whether suspect isolating in-place or confirmed isolation in the dedicated COVID-19 isolation area, should avoid communal dining and group activities regardless of community levels or the facility’s outbreak status. Residents who are close contacts may continue participating in group activities while wearing well-fitting masks with good filtration but should not participate in communal dining through day 10 since their last exposure (day 0 being day of exposure). These activities may take place indoors or outdoors regardless of the facility’s outbreak status and regardless of the resident’s vaccination status. Facilities should continue to follow all infection prevention and control measures to conduct communal dining and group activities safely including but not limited to the following:
Visitation
Table 2. Infection Prevention & Control Measures for Visitation | ||
---|---|---|
Residents Not in Isolation | Residents in Isolation (dedicated COVID-19 isolation area or in-place) | |
Safe Entry Policies |
* Visitors should follow the same criteria used to discontinue isolation for SNF residents (please see table 4). Criteria for the general public does not apply in this setting given the high-risk nature of these facilities and their residents. |
* Visitors should follow the same criteria used to discontinue isolation for SNF residents (please see table 4). Criteria for the general public does not apply in this setting given the high-risk nature of these facilities and their residents. |
Masks | Based on CMS QSO-20-39-NH-Revised, visitors should wear well-fitting masks when indoors if:
|
All visitors should be offered an N95 respirator or higher and perform a seal check. Residents should also wear well-fitting masks if safe and practical. |
Other Infection Prevention and Control |
|
|
Physical Distancing | There is no recommendation to physically distance or avoid physical contact (e.g., hugs, holding hands) between a resident and their visitor(s), regardless of vaccination status. However, physical distancing should be followed during large indoor gatherings to avoid crowding especially in poorly ventilated areas. | |
Location of Visit |
|
|
Surveillance. Active symptom screening of residents and staff are the basis of infectious disease surveillance. Prompt identification and management of symptomatic individuals (testing and isolation), including those with mild symptoms, can help mitigate transmission.
Testing Methods
Table 3. Summary of Testing Guidance
The table below contains recommendations for COVID-19 testing in SNFs based upon CMS QSO 20-38-NH-Revised and the CDC “Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the COVID-19 Pandemic” guidance. Please note when there are differences in testing requirements, the most conservative testing guidance should be followed.
NOTE: Interpretation of COVID-19 viral test results does not change after an individual has received COVID-19 vaccination.
Testing Indication | Residents | Staff |
---|---|---|
Symptomatic Individual with symptoms of COVID-19 including mild symptoms, regardless of vaccination status NOTE: If a staff or resident develops new symptoms consistent with COVID-19 ≤ 90 days of a prior positive test and an alternative etiology cannot be identified, then retesting with an antigen test can be considered in consultation with the medical director, infectious disease, or infection control experts. |
One antigen test immediately and if negative, one PCR/NAAT test collected 48 hrs later for a total of at least 2 tests; OR One PCR/NAAT test immediately. During the influenza season, residents with acute respiratory symptoms should also be tested for influenza as per LAC DPH's guidance on management of influenza in context of COVID-19 in SNFs. |
Test immediately. Please see LAC DPH’s COVID-19 Infection Prevention Guidance for Healthcare Personnel. |
Contact Tracing Testing One or more case(s) identified in a resident or staff AND contact tracing is feasible (i.e., exposure is known and limited and there are staffing resources to support rapid contact tracing). |
Serially test residents who are close contacts1 and exposed staff identified in contact tracing 3 times on days 1, 3, and 5 after the last exposure (day 0).
Antigen tests or PCR/NAAT tests (if TAT is <48 hrs) may be utilized. If additional resident case(s) are identified during close contact testing, then the facility should immediately broaden their testing strategy to group-level or facility-level response testing serially every 3-7 days for PCR/NAAT tests (if TAT <48 hrs) or every 3 days for antigen tests until there are no new cases identified among residents or staff for 14 days. Any asymptomatic residents with positive antigen test results (suspect case) must immediately be isolated in place pending results of confirmatory PCR/NAAT tests. Please see “Isolation and Quarantine” section. |
|
Group-level testing2 involves all residents and staff in the same area (unit, wing, nursing station area, etc.), regardless of vaccination status, when ≥1 case is identified in a resident or staff. This is the recommended initial response testing strategy when the exposure is suspected to be limited to the same area of the facility. Facility-wide testing2 involves all residents and staff in the facility, regardless of vaccination status, when ≥1 case is identified in a resident or staff. This is the recommended initial response testing strategy when widespread exposure is suspected, the exposure level is unknown, or contact tracing is unreliable or unable to be performed in a timely way. |
For initial response testing strategy: serially test on days 1, 3, and 5 after exposure (day 0). If the initial round of testing on days 1, 3, and 5 yields additional cases among residents, then response testing should be further broadened to facility-wide if not done so already. Subsequent rounds of response testing should be every 3-7 days for PCR/NAAT tests (if TAT <48 hrs) or every 3 days for antigen tests until there are no new cases identified among residents or staff for 14 days. Any asymptomatic residents with positive antigen test results (suspect case) should be immediately be isolated in place pending results of confirmatory PCR/NAAT testing. Please see “Isolation and Quarantine” section. |
|
Routine screening testing2: Individuals who are asymptomatic, not a new admission or re-admission, not a close contact, and when there is no facility-wide or group-level post-exposure or response testing. | Generally not recommended, but may be performed at the discretion of the facility. If a facility chooses to conduct routine screening testing, it should not be based on vaccination status and resident rights should be respected (i.e., resident refusal should not result in quarantine or influence their rooming or placement).
NOTE: Facilities should maintain testing capacity and have the ability to ramp up testing in the event routine screening testing is required again at a future date. |
|
New Admissions and Re-Admissions2 who are asymptomatic without a current diagnosis of COVID-19 at the time of admission and without known close contacts.
Residents who have returned after leaving the facility for 24 hours or longer should be managed as an admission. |
Serially testing a total of 3 times on days 0, 3, and 5 after admission (day 0) is a strong recommendation when the CDC Community Level is high and a consideration at lower transmission.
Antigen tests or PCR/NAAT tests (if TAT is <48 hrs) may be utilized. If admission testing is performed, this does not necessarily mean quarantine is indicated. Please see “Isolation and Quarantine” section. |
Not applicable. |
Footnotes:
Retesting Previously Positive Staff/Residents
|
Refusal of Testing
Please refer to CMS QSO 20-38-NH-Revised. The following are some clarifications for resident refusal of testing:
The following summary of isolation, quarantine, and related infection control guidance is based on CDPH AFL 23-12, CMS QSO 20-38-NH-Revised, and the CDC guidance “Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic.”
Table 4. Summary of Isolation and Infection Control Guidance for Residents
Who | Infection Control Measures |
---|---|
Confirmed COVID-19 Case |
|
Suspect COVID-19 Case:
|
|
Close contacts (asymptomatic) |
|
Residents undergoing group-level or facility-wide post-exposure and response testing who are asymptomatic and not part of the above categories |
|
New admission, re-admissions, or returning after leaving the facility >24 hrs who are asymptomatic and not part of the above categories |
|
Footnotes: * Special staffing considerations for the designated COVID-19 Isolation Area:
**The following are considered severely immunocompromising conditions as per CDC: actively receiving chemotherapy for cancer, hematologic malignancies, being within one year from receiving a hematopoietic stem cell or solid organ transplant, untreated HIV infection with CD4 count <200, combined primary immunodeficiency disorder, taking immunosuppressive medications (e.g., drugs to suppress rejection of transplanted organs or to treat rheumatologic conditions such as mycophenolate, rituximab, prednisone dose >20mg/day for more than 14 days), or other severely immunocompromised condition as determined by the resident’s primary/treating physician. ***Quarantine involves 1) restricting the resident to their room as much as possible if safe and practical; 2) resident wearing well-fitting masks indoors when not in their rooms; and 2) staff wearing full PPE per COVID transmission based precautions when providing care or entering a room where the resident is (resident room, shower room, rehab gym, etc.). Residents in quarantine should be managed in-place; avoid movement of residents that could lead to new exposures. |
Facilities should follow the LAC DPH COVID-19 Infection Prevention Guidance for Healthcare Personnel.
Symptom monitoring
Return to work
For return to work refer to the following sections:
Facilities should communicate COVID-19 status (suspect or confirmed infection) to the receiving facility (hospital, outpatient clinic, dialysis center, dental clinics) before transfer as per CDC. Healthcare facilities are strongly encouraged to use the LAC DPH Infectious Organism Transfer Form.
During outbreaks, facilities should communicate with their Public Health outbreak investigation team prior to any lateral transfer to another SNF. On a case-by-case basis, Public Health may restrict lateral transfers to other SNFs during outbreaks, especially of residents who are suspect or confirmed COVID-19 cases.
Receiving SNFs should not require a negative test result for COVID-19 as criteria for admission or readmission. Instead, SNFs and hospitals should proactively communicate and collaborate to facilitate the safe, timely, and appropriate placement of SNF residents. SNFs should be prepared to provide care safely without putting existing residents at risk, including maintaining the ability to quickly re-establish a designated COVID-19 isolation area (formerly known as a “Red Zone”) as per CDPH AFL 23-12. Please reach out to LAC DPH at LTC_NCoV19@ph.lacounty.gov for questions and/or help with transfers related to COVID-19 infection control.
In cases of hospital overload, this transfer guidance may be adjusted by LAC DPH.Per LAC DPH’s Updated COVID-19 Reporting Requirements Health Officer Order and the CDPH Public Health Officer Order, SNFs are required to report within 24 hours:
*NOTE: The current COVID-19 outbreak definition for SNFs in Los Angeles County is at least one PCR/NAAT laboratory confirmed case of COVID-19 (symptomatic or asymptomatic) OR at least one symptomatic case with a positive SARS-CoV-2 antigen result in a SNF resident who has been at the facility for at least 7 days.
For more details, please see the LAC DPH COVID-19 Case Reporting Protocol for SNFs or visit the LAC DPH COVID-19 Provider Reporting page.
Relevant Webinars
Resources